Welcome to our dedicated page for Lexaria Bioscien SEC filings (Ticker: LEXXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LEXXW SEC filings page on Stock Titan is intended to aggregate regulatory documents associated with Lexaria Bioscience Corp.’s Nasdaq-listed securities, including its warrants trading under the symbol LEXXW. While no specific SEC filings are provided in the data above, Lexaria’s public news releases reference the use of shelf registration statements on Form S‑3 and registered direct offerings of common stock, often paired with concurrent private placements of unregistered warrants. For investors following LEXXW, formal SEC filings are the primary source for detailed information on these transactions and related terms.
In its announcements, Lexaria notes that shares of common stock are offered under an effective Form S‑3 registration statement, with prospectus supplements and base prospectuses filed with the U.S. Securities and Exchange Commission. The company also states that certain warrants, including those associated with LEXXW, are issued in private placements under exemptions such as Section 4(a)(2) of the Securities Act and Regulation D, and that the underlying shares may later be registered for resale. These elements are typically documented in SEC filings such as prospectus supplements, registration statements, and related exhibits.
On Stock Titan, users can use the LEXXW filings page to locate and review Lexaria’s publicly available SEC submissions once they are linked, including registration statements, prospectus supplements, and other offering-related documents. In addition, investors may look for annual and quarterly reports, if applicable to Lexaria’s common stock, to understand how warrant offerings, research and development expenditures, and capital allocation are discussed in a broader financial and risk context.
Stock Titan’s platform enhances this process by providing structured access to filings and AI-powered tools that summarize key points, highlight offering terms, and help interpret complex regulatory language. For LEXXW, this can assist users in understanding how warrant structures, exercise prices, expirations, and related financing activities fit into Lexaria Bioscience Corp.’s overall capital markets and R&D strategy as described in its public communications.
Lexaria Bioscience Corp. reported that on February 4, 2026 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Capital Market’s minimum bid price requirement of $1.00 per share. The stock remains listed and continues to trade under the symbol LEXX.
The company has 180 calendar days, until August 3, 2026, for its closing bid price to be at or above $1.00 per share for at least 10 consecutive business days (and up to 20 at Nasdaq’s discretion) to regain compliance. If it does not do so, Lexaria may qualify for an additional 180‑day period if it meets all other initial listing standards and notifies Nasdaq of plans to cure the deficiency, potentially including a reverse stock split.
If Lexaria cannot meet these conditions, Nasdaq may move to delist the stock, and the company would then have the opportunity to appeal. Lexaria states that it intends to actively monitor its share price and evaluate options to address the deficiency, but it notes there is no assurance it will regain or maintain compliance.
Lexaria Bioscience Corp. reported the results of its annual shareholder meeting held on January 27, 2026. A total of 8,380,389 shares, or 37.71% of issued share capital as of December 1, 2025, were represented in person or by proxy.
Shareholders elected all seven director nominees, with approval levels ranging from 73.6% to 96.4%. They also approved the appointment of Malone Bailey LLP as auditors, with 97.0% of votes cast in favor.
In addition, shareholders voted to ratify the lawful actions of the directors for the past year, with 90.0% approval, signaling broad support for the company’s current leadership and governance decisions.
FAQ
What is the current stock price of Lexaria Bioscien (LEXXW)?
